Englander Institute for Precision Medicine
News & Events

News & Events

Join our frequent seminar series, case conferences, consortium meetings, and more!

Mapping the Evolution of Urinary Tract Cancer Cells

March 18, 2024

Researchers at Weill Cornell Medicine have performed the most comprehensive analysis to date of cancer of the ureters or the urine-collection cavities in the kidney, known as upper tract urothelial carcinoma (UTUC).  The study, which compared the characteristics of primary and metastatic tumors, provides new insights into the biology of these aggressive cancers and potential ways to treat them.

EIPM Researchers Earn Cancer Grand Challenges Funding Award to Study Cancer Inequity

March 6, 2024

Weill Cornell Medicine is part of an international team that has been awarded funding of up to $25 million over five years by Cancer Grand Challenges to study the causes of cancer inequities.

Deciphering the Male Breast Cancer Genome

March 5, 2024

Male breast cancer has distinct alterations in the tumor genome that may suggest potential treatment targets, according to a study by Weill Cornell Medicine investigators. They have conducted the first whole genome sequencing analysis of male breast cancer, which looked at the complete DNA landscape of tumor samples from 10 patients.

Oncologist Receives Prestigious MERIT Grant from the National Cancer Institute for Bladder Cancer Research

March 4, 2024

Bishoy M. Faltas, MD, a medical oncologist at NewYork-Presbyterian/Weill Cornell Medicine and Director of Bladder Cancer Research at the Englander Institute for Precision Medicine at Weill Cornell Medicine, was awarded a MERIT grant from the National Cancer Institute at the National Institutes of Health to advance his research into the role of APOBEC3 enzymes in metastatic bladder cancer.

Genetic signature may predict lung cancer response to immunotherapy

February 27, 2024

A new study has identified a set of 140 genes that may help predict enhanced disease-free survival in patients with non-small-cell lung cancer (NSCLC) treated with a combination of immunotherapy and low-dose radiation.

The results, published Feb. 23 in Cell Medicine Reports, suggested that this “gene signature” could be used to identify a subclass of lung tumors that is more likely to be eradicated by immunotherapies.

Genetic Signature May Predict Response to Immunotherapy for Non-Small Cell Lung Cancer

February 23, 2024

A new study identified a set of 140 genes that may help predict enhanced disease-free survival in patients with non-small cell lung cancer (NSCLC) treated with a combination of immunotherapy and low-dose radiation. The results, published in Cell Medicine Reports on Feb.

Less Invasive Early Lung Cancer Study Receives Top 10 Clinical Research Achievement Award

February 22, 2024

A Weill Cornell Medicine-led research team has been awarded a 2024 Top 10 Clinical Research Achievement Award from the Clinical Research Forum in recognition of an influential 2023 New England Journal of Medicine study on early-stage lung cancer resection.

February 2024 EIPM Director's Memo

February 5, 2024

Dear Members of the Englander Institute,

Thank you all for a very productive January!

Who’s Afraid of Early Cancer Detection?

February 4, 2024

A diagnosis of pancreatic cancer usually means a quick death—but not for Roger Royse, who was in Stage II of the disease when he got the bad news in July 2022. The five-year relative survival rate for late-stage metastatic pancreatic cancer is 3%—which means that patients are 3% as likely to live five years after their diagnosis as other cancer-free individuals.

Task force offers guidance to researchers on use of AI

January 22, 2024

A multidisciplinary task force of Cornell faculty and staff has issued a report offering perspectives and practical guidelines for the use of generative artificial intelligence (GenAI) in the practice and dissemination of Cornell’s academic research.

Weill Cornell Medicine Englander Institute for Precision Medicine 413 E 69th Street
Belfer Research Building
New York, NY 10021